Aasim Sheikh, MD
Gastroenterology · Marietta, GANPI 1841249133
Payments from drug & device makers
Across 1,433 payments — averaging $4185.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intercept Pharmaceuticals, Inc.$1.5M
- Gilead$1M
- Genentech, Inc.$473K
- Madrigal Pharmaceuticals$371K
- Novartis$360K
- AbbVie$357K
- plus $1.9M from 29 others
Across 26 payments — averaging $2438.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$61K
- Sanofi US Services Inc.$2K
What the payments were for
- Consulting fees$8,42066%
- Travel & lodging$1,93915%
- Food & beverage$2,31518%
- Education$1441%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intercept Pharmaceuticals, Inc. | 132 | $1,460,281 |
| Gilead | 155 | $1,038,907 |
| Genentech, Inc. | 50 | $472,667 |
| Madrigal Pharmaceuticals | 83 | $371,336 |
| Novartis | 16 | $360,286 |
| AbbVie(2 entities) | 100 | $356,934 |
| Novo Nordisk AS | 597 | $323,352 |
| GSK | 49 | $292,198 |
| E.r. Squibb & Sons, L.L.C. | 12 | $286,256 |
| Roche Products Limited | 101 | $281,578 |
| Boehringer Ingelheim | 6 | $206,411 |
| Eli Lilly | 8 | $130,042 |
| Janssen Research & Development, LLC | 44 | $107,883 |
| Bristol Myers Squibb | 3 | $102,436 |
| Intercept Pharma Europe Ltd. | 6 | $66,197 |
| AstraZeneca | 2 | $61,219 |
| Sanofi US Services Inc. | 3 | $26,822 |
| Braintree Laboratories, Inc. | 6 | $25,004 |
| Bausch Health US, LLC | 2 | $10,668 |
| Boehringer Ingelheim RCV GmbH & Co KG | 28 | $9,763 |
| Redhill Biopharma Inc. | 2 | $4,977 |
| Seres Therapeutics, Inc. | 2 | $1,601 |
| Boston Scientific | 2 | $183 |
| Medtronic | 2 | $171 |
| Johnson & Johnson | 5 | $164 |
| Mallinckrodt Hospital Products Inc. | 1 | $125 |
| Fujifilm Healthcare Americas Corporation | 1 | $112 |
| Ipsen Biopharmaceuticals, Inc | 4 | $87 |
| Ardelyx, Inc. | 3 | $54 |
| Novo Nordisk | 2 | $52 |
| Sanofi | 1 | $28 |
| Phathom Pharmaceuticals, Inc. | 2 | $25 |
| Lilly USA, LLC | 1 | $21 |
| Pfizer | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LJN452$7,536
- OCALIVA$1,920
- TheraSphere Y90 Glass Microspheres 10 GBq$166
- REZDIFFRA$149
- INTERSTIM$146
- TERLIVAZ$125
- uTASWako AFP-L3$112
- Non-Covered Product$101
How this compares
$5,997,868 in reported general payments places this provider in the 95th percentile of 492 gastroenterology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZenpepLipase/Protease/Amylase | 37 | $84,245 |
| XifaxanRifaximin | 19 | $57,615 |
| VemlidyTenofovir Alafenamide | 31 | $46,637 |
| LinzessLinaclotide | 64 | $42,636 |
| CreonLipase/Protease/Amylase | 13 | $25,836 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 73 | $5,036 |
| Bethanechol Chloride | 25 | $2,788 |
| Ursodiol | 28 | $2,571 |
| Famotidine | 117 | $1,906 |
| Omeprazole | 238 | $1,847 |
| Pantoprazole Sodium | 195 | $1,457 |
| Colestipol Hcl | 28 | $1,118 |
| Budesonide DrBudesonide | 12 | $1,016 |
| Sucralfate | 39 | $999 |
| Balsalazide Disodium | 13 | $851 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Creon | $356,934 | $68,47177 claims |
| GileadVemlidy | $1,038,907 | $46,63731 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 492 gastroenterology providers in Georgia.
Other gastroenterology in Marietta
- Michael LevineMarietta$21K
- Anna LongacreMarietta$19K
- Douglas WolfAtlanta$6.4M
- Shahriar SedghiMacon$5.4M
- Jeffrey WilliamsAthens$2.5M
- Michael GalambosAtlanta$1.8M
- Nitin GuptaAtlanta$1.7M
- Bruce SalzbergSuwanee$1.4M
- Heba IskandarAtlanta$978K
- David RausherDecatur$907K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.